LBX Pharmacy Chain Toekomstige groei

Future criteriumcontroles 1/6

LBX Pharmacy Chain zal naar verwachting groeien in winst en omzet met respectievelijk 18.2% en 12.7% per jaar. De winst per aandeel zal naar verwachting groeien met 19.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 14.5% zijn.

Belangrijke informatie

18.2%

Groei van de winst

19.8%

Groei van de winst per aandeel

Consumer Retailing winstgroei	42.2%
Inkomstengroei	12.7%
Toekomstig rendement op eigen vermogen	14.5%
Dekking van analisten	Good
Laatst bijgewerkt	19 Nov 2024

Recente toekomstige groei-updates

Recent updates

We Think You Can Look Beyond LBX Pharmacy Chain's (SHSE:603883) Lackluster Earnings

Nov 06

LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Sep 06

Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?

Sep 02

Take Care Before Jumping Onto LBX Pharmacy Chain Joint Stock Company (SHSE:603883) Even Though It's 30% Cheaper

Jul 03

Here's Why We Think LBX Pharmacy Chain (SHSE:603883) Is Well Worth Watching

Jun 08

LBX Pharmacy Chain (SHSE:603883) Seems To Use Debt Quite Sensibly

May 21

There Is A Reason LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Undemanding

Apr 22

Winst- en omzetgroeiprognoses

SHSE:603883 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	30,199	1,294	2,584	2,948	12
12/31/2025	26,741	1,121	2,379	2,725	13
12/31/2024	22,841	859	2,532	2,054	10
9/30/2024	22,628	843	1,855	2,556	N/A
6/30/2024	22,566	918	1,648	2,304	N/A
3/31/2024	22,536	959	1,741	2,298	N/A
12/31/2023	22,437	929	2,109	2,730	N/A
9/30/2023	22,441	892	1,500	1,841	N/A
6/30/2023	21,995	842	1,990	2,337	N/A
3/31/2023	21,475	835	2,558	2,903	N/A
12/31/2022	20,176	785	2,006	2,314	N/A
9/30/2022	18,192	746	2,201	2,530	N/A
6/30/2022	17,226	720	1,910	2,249	N/A
3/31/2022	16,198	683	1,586	2,112	N/A
12/31/2021	15,696	669	1,820	2,298	N/A
9/30/2021	15,128	666	1,654	2,082	N/A
6/30/2021	14,741	691	1,586	2,058	N/A
3/31/2021	14,323	653	1,362	1,693	N/A
12/31/2020	13,967	621	1,053	1,447	N/A
9/30/2020	13,413	602	919	1,362	N/A
6/30/2020	12,816	575	669	1,042	N/A
3/31/2020	12,218	545	634	1,036	N/A
12/31/2019	11,663	509	606	1,033	N/A
9/30/2019	11,069	505	423	1,033	N/A
6/30/2019	10,567	484	63	990	N/A
3/31/2019	9,988	464	1	883	N/A
12/31/2018	9,471	435	40	913	N/A
9/30/2018	9,015	421	-30	559	N/A
6/30/2018	8,484	401	N/A	568	N/A
3/31/2018	7,984	388	N/A	518	N/A
12/31/2017	7,501	371	N/A	498	N/A
9/30/2017	7,036	363	N/A	609	N/A
6/30/2017	6,780	343	N/A	413	N/A
3/31/2017	6,494	331	N/A	420	N/A
12/31/2016	6,094	297	N/A	313	N/A
9/30/2016	5,673	285	N/A	331	N/A
6/30/2016	5,250	265	N/A	280	N/A
3/31/2016	4,850	254	N/A	257	N/A
12/31/2015	4,568	241	N/A	257	N/A
9/30/2015	4,331	226	N/A	217	N/A
6/30/2015	4,178	218	N/A	276	N/A
3/31/2015	4,063	212	N/A	266	N/A
12/31/2014	3,943	202	N/A	247	N/A
12/31/2013	3,321	161	N/A	137	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 603883 ( 18.2% per jaar) ligt boven de spaarquote ( 2.8% ).

Winst versus markt: De winst van 603883 ( 18.2% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 26.2% per jaar).

Hoge groeiwinsten: De winst van 603883 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 603883 ( 12.7% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 13.8% per jaar).

Hoge groei-inkomsten: De omzet van 603883 ( 12.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 603883 zal naar verwachting over 3 jaar laag zijn ( 14.5 %).

LBX Pharmacy Chain Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 12% to CN¥26.64

Consensus EPS estimates fall by 29%

Price target increased by 8.1% to CN¥45.36

Price target increased by 7.5% to CN¥43.11

Price target increased to CN¥41.97

Price target decreased to CN¥58.58

Recent updates

We Think You Can Look Beyond LBX Pharmacy Chain's (SHSE:603883) Lackluster Earnings

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of CN¥0.33 per share

LBX Pharmacy Chain Joint Stock Company to Report Q3, 2024 Results on Oct 30, 2024

Price target decreased by 12% to CN¥26.64

Investor sentiment deteriorates as stock falls 17%

Consensus EPS estimates fall by 29%

LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Right But Growth Is Lacking After Shares Rocket 30%

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Now 23% undervalued after recent price drop

Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?

Take Care Before Jumping Onto LBX Pharmacy Chain Joint Stock Company (SHSE:603883) Even Though It's 30% Cheaper

Investor sentiment deteriorates as stock falls 17%

LBX Pharmacy Chain Joint Stock Company to Report First Half, 2024 Results on Aug 30, 2024

Dividend increased to CN¥0.66

Here's Why We Think LBX Pharmacy Chain (SHSE:603883) Is Well Worth Watching

LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024

LBX Pharmacy Chain (SHSE:603883) Seems To Use Debt Quite Sensibly

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

There Is A Reason LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Undemanding

LBX Pharmacy Chain Joint Stock Company to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment improves as stock rises 18%

LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: EPS: CN¥1.36 (vs CN¥1.26 in FY 2021)

Now 21% undervalued after recent price drop

Price target increased by 8.1% to CN¥45.36

Now 21% undervalued after recent price drop

Price target increased by 7.5% to CN¥43.11

Price target increased to CN¥41.97

Now 22% undervalued

Now 21% undervalued

Less than half of directors are independent

Third quarter 2022 earnings: EPS misses analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to CN¥58.58

Consensus EPS estimates fall by 21%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CN¥63.49

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.34 in 3Q 2020)

LBX Pharmacy Chain Joint Stock Company (SHSE:603883) agreed to acquire 51% stake in Hebei Hua Tuo Pharmacy Medicine Chain Co., Ltd. from Zhang Weijun, Tian Jinping, Ma Zhirong and Guo Zhihong fro CNY 1.4 billion.

Price target decreased to CN¥75.25

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.35 in 2Q 2020)

Price target decreased to CN¥79.67

Price target decreased to CN¥86.50

First quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.49 in 1Q 2020)

New 90-day low: CN¥61.85

New 90-day high: CN¥81.64

Investor sentiment improved over the past week

New 90-day low: CN¥63.60

New 90-day low: CN¥65.89

New 90-day low: CN¥67.21

Price target raised to CN¥97.98

Laobaixing Reportedly in Merger Talks with Yixintang

Third quarter earnings released

Laobaixing Pharmacy Chain Joint Stock Company to Report Q3, 2020 Results on Oct 30, 2020

Price target raised to CN¥89.75

New 90-day high - CN¥87.00

New 90-day high - CN¥87.00

First half earnings released

Laobaixing Pharmacy Chain Joint Stock Company to Report First Half, 2020 Results on Aug 21, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen